GSK(US:GSK) Di Yi Cai Jing·2026-01-08 08:44Group 1 - GSK's Bepirovirsen has achieved primary endpoints in two key Phase III clinical trials, potentially leading to the first antiviral therapy for functional cure of chronic hepatitis B (CHB) with a limited 6-month treatment course [1] - The drug is a novel antisense oligonucleotide (ASO) that directly inhibits viral replication, with GSK planning to initiate global regulatory approval in Q1 of this year [1] - Analysts suggest that even a 15% to 20% functional cure rate among hepatitis B patients would significantly alter global treatment outcomes, as current therapies do not achieve notable functional cure rates [1][2] Group 2 - Chronic hepatitis B affects over 250 million people globally and is a leading cause of liver cancer, with over 1 million deaths attributed to it in 2022 according to WHO [2] - Current standard treatments, primarily nucleos(t)ide analogs (NAs), can suppress viral replication but do not eliminate the virus, requiring lifelong medication for patients [2] - The potential approval of new therapies like Bepirovirsen could fundamentally change treatment outcomes for hepatitis B in China, with other pharmaceutical giants like Roche and Johnson & Johnson also developing related therapies [3]